![Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial - The Lancet Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial - The Lancet](https://www.thelancet.com/cms/asset/ace7fa3d-5e0d-4939-a891-27d48597253b/gr1.jpg)
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial - The Lancet
![Leukotrienes and Other Products of the 5-Lipoxygenase Pathway — Biochemistry and Relation to Pathobiology in Human Diseases | NEJM Leukotrienes and Other Products of the 5-Lipoxygenase Pathway — Biochemistry and Relation to Pathobiology in Human Diseases | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1990/nejm_1990.323.issue-10/nejm199009063231006/production/images/img_medium/nejm199009063231006_f1.jpeg)
Leukotrienes and Other Products of the 5-Lipoxygenase Pathway — Biochemistry and Relation to Pathobiology in Human Diseases | NEJM
![Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial - The Lancet Diabetes Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial - The Lancet Diabetes](https://www.thelancet.com/cms/asset/a6f45dad-0f40-48ae-8f89-2971051b7477/gr1.jpg)